NATICK, Mass., May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando, Fla. More than 24 clinical presentations will feature new data and analyses on products including the Boston Scientific SpyGlass® Direct Visualization System, WallFlex® Biliary RX Stent System and Expect® 19 Flex Endoscopic Ultrasound Aspiration Needle.
"The insights and data included in these presentations further demonstrate the commitment of Boston Scientific to provide value to healthcare professionals and patients," said David Pierce, president, Endoscopy, Boston Scientific. "As we continue to evaluate and improve our broad portfolio for the diagnosis and treatment of gastrointestinal diseases, we look forward to continuing to collaborate with healthcare professionals to provide breakthrough innovations designed to enhance patient lives."
The SpyGlass Direct Visualization System, WallFlex Stents and Expect 19 Flex Needle will be available for demonstration at the Boston Scientific booth, #1549, throughout DDW. The company will also offer hands-on product demonstration sessions in its Simulated Clinical Endoscopy Suites and at its booth stations for GI Stents, Core Biliary, Visualization and Therapeutics for ERCP, Hemostasis, Dilation, Tissue Acquisition and Enteral Access. For more information on Boston Scientific endoscopy products, visit www.bsci.com/endo-resources.
Schedule of Key Podium and Poster Presentations (partial listing)
Poster presentations are scheduled from 8:00 a.m. to 5:00 p.m. ET at the Orange County Convention Center in Hall West A1. All clinical data results are under embargo until the start of each scientific presentation and 8:00 a.m. for poster presentations.
Saturday, May 18
Sunday, May 19
Monday, May 20
Tuesday, May 21
Digestive Disease Week® (DDW®) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18 – 21, 2013, at the Orange County Convention Center, Orlando, FL. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, clinical trials and the importance of their results, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Global Media Relations
Boston Scientific Corporation
Boston Scientific Corporation
 Use of the WallFlex Biliary RX Fully Covered Stent for the treatment of benign strictures or stenoses has not been cleared for use in the United States.
SOURCE Boston Scientific Corporation